



# MPDL3280A PEC Agenda November 19, 2014

*Ramada Plaza Basel Hotel, Room Geneva 1, 3<sup>rd</sup> floor*

Time	Topic	Leader
8:30 – 9:00	Registration, Welcome and Introductions	All, G. Papa, C. Berardo
9:00 – 9:15	MPDL3280A Development Program	L. Veronese
<b>Session I – MPDL3280A in metastatic UBC</b>		
9:15 – 9:40	Unmet Medical Need and the Potential for Immunotherapy (MPDL3280A) in the Treatment of UBC	T. Powles
9:40 – 11:15	2L UBC: Identifying the Appropriate Comparator(s) across Geographies	Discussion
11:15 – 11:45	Coffee Break	
<b>Session II – Immunotherapy Endpoints</b>		
11:45 – 12:00	Immunotherapy endpoints – clinician perspective	T. Powles
12:00 – 13:00	Payer Perspective on Immunotherapy Endpoints	Discussion
13:00 – 13:10	Summary of the Morning Sessions' Discussion	P. Oh
13:10 – 14:00	Lunch Break	
<b>Session III – MPDL3280A in metastatic NSCLC</b>		
14:00 – 14:15	Unmet Medical Need and the Potential of Immunotherapy (MPDL3280A) in the Treatment of NSCLC	F. De Marinis
14:15 – 16:00	1L NSCLC: Identifying the Appropriate Comparator(s) across Geographies	Discussion
16:00 – 16:30	Coffee Break	
<b>Session IV – Companion Diagnostic</b>		
16:30 – 17:30	Impact of Companion Diagnostic(s) on MPDL3280A Market Access Strategy	Discussion
17:30 – 17:45	Summary of the Afternoon Sessions' Discussion	P. Sawicki
17:45 – 18:00	Summary and Conclusions	G. Papa C. Berardo